Lilly looks in strong position to challenge Wegovy in obesity

While investors await the outcome of a head-to-head trial featuring GLP-1 heavyweights semaglutide and tirzepatide, a large retrospective observational study points to a likely winner.

Marketed by Novo Nordisk (NOV: N) as Wegovy in obesity, semaglutide was the first to market but is generally believed to be outmatched in its capacity to promote weight loss by Eli Lilly’s (NYSE: LLY) dual-action rival, which is sold as Zepbound in this indication.

Published in JAMA Internal Medicine, the latest data appear to confirm that expectation.